Actavis renamed as Allergan
This article was originally published in Scrip
Actavis has now changed its name to Allergan and began trading under its new moniker on the New York Stock Exchange on 15 June. The name change follows the acquisition of Allergan in March 2015 and the approval of the name change by Actavis shareholders on 5 June; it announced its intention to change names in February. The company's US and Canadian generics business is to retain the Actavis name. CEO and president Brent Saunders said, "By adopting the Allergan name, we are ensuring that our corporate identity reflects the transformation of our company within the pharmaceutical industry and our position as a dynamic new breed of company – a leader in growth pharma." The combination of the two firms has created a new top-10 pharma company by revenues.
You may also be interested in...
Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma
Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.
Allergan's Fishing For Deals, But Don't Expect A Big Catch
Allergan PLC will use its $36bn in after-tax cash and equity from the sale of its generics business to Teva Pharmaceutical Industries Ltd. to reduce debt, buy back shares of its stock, and to acquire companies or assets, but don't expect Allergan to catch any big fish in its dealmaking net.
Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space
Listen to expert perspectives from Tracey Parker, Vice President, Biometrics, Advanced Clinical and Rebecca Starkie, Senior Global Patient Engagement Director, Advanced Clinical on the recent history of DEI in clinical trials and the barriers to patient participation. Examine the key drivers that have influenced the development of diversity, equity, and inclusion programs for clinical trials.